Pushing Therapeutic Boundaries in CLLJoint Live Web Broadcast with CLL Society and PeerView Institute Recorded on June 14, 2021 Continuous or fixed-duration therapy with targeted agents, including BTK and BCL-2 inhibitors, is the new standard for management of chronic lymphocytic leukemia (CLL). New clinical questions that are pushing the